Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hypophosphatasia
100%
Young children
100%
Infant Patients
100%
Asfotase Alfa
100%
Extension Trial
100%
Life-threatening
22%
Motor Function
22%
Treatment Duration
22%
Craniosynostosis
22%
Treatment-related Adverse Events
22%
Cognitive Function
22%
Respiratory Support
22%
Patient Global Impression of Change
22%
Pneumonia
11%
Patient-completed
11%
Canada
11%
Pyrexia
11%
Adverse Events
11%
Number of Patients
11%
Change Score
11%
Skeletal Mineralization
11%
Enzyme Replacement Therapy
11%
Chronic Hepatitis
11%
Commercially Available
11%
Serious Adverse Events
11%
Healing
11%
Phase II Trial
11%
Near-complete
11%
Dosage Adjustment
11%
Patient Weight
11%
Height-for-age Z-score
11%
Upper Respiratory Tract Infection
11%
Sustained Improvement
11%
Safety Analysis
11%
Skeletal Manifestations
11%
Bayley Scales of Infant Development
11%
Toddler Development
11%
EudraCT
11%
Efficacy Analysis
11%
Fine Motor
11%
Equivalent Score
11%
Complete Healing
11%
Respiratory Function
11%
Gross Motor
11%
Long-term Tolerability
11%
United Arab Emirates
11%
Oct6
11%
Conductive Deafness
11%
Medicine and Dentistry
Arm
100%
Hypophosphatasia
100%
Asfotase Alfa
100%
Adverse Event
44%
Craniofacial Synostosis
22%
Motor Performance
22%
Assisted Ventilation
22%
Enzyme Replacement Therapy
11%
Chronic Hepatitis
11%
Mineralization
11%
Respiratory Physiology
11%
Upper Respiratory Tract Infection
11%
Bayley Scales of Infant Development
11%
Conductive Hearing Loss
11%
Pharmacology, Toxicology and Pharmaceutical Science
Hypophosphatasia
100%
Asfotase Alfa
100%
Adverse Event
44%
Craniofacial Synostosis
22%
Replacement Therapy
11%
Chronic Hepatitis
11%
Tolerability
11%
Upper Respiratory Tract Infection
11%
Conduction Deafness
11%